We use cookies on our website. Carry on browsing if you’re happy with this or find out more

News

:

Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise

Plate Assay in Lab

Source: Kymab

Kymab presented data on KY1044, a novel anti-ICOS antibody, and KY1055, a novel ICOS/PD-L1 bispecific antibody, at the American Association for Cancer Research Annual Meeting held in Chicago, IL, April 14-18, 2018

Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise

Cambridge, UK, 18 April 2018: Kymab Group Limited ("Kymab"), a biopharmaceutical company developing fully human monoclonal antibody therapeutics, presented data on KY1044 (a novel anti-ICOS antibody) and KY1055 (a novel ICOS/PD-L1 bispecific antibody), at the American Association for Cancer Research ("AACR") Annual meeting held April 14-18, 2018 in Chicago, Illinois, USA.

The AACR Annual Meeting covers the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations.

Notes to Editors

About Kymab's AACR Posters

KY1044 poster

Title: The combination of immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumour response (#2792)

Session Title: Therapeutic Antibodies, Including Engineered Antibodies 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM - 5:00 PM

Link to the Poster (1.4 Mb PDF)

KY1055 poster

Title: KY1055, a novel ICOS/PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo. (#LB-153)

Session Title: Late-Breaking Research: Clinical Research 1

Session Date and Time: Monday Apr 16, 2018 1:00 PM - 5:00 PM

Link to the Poster (450 kb PDF)

About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.

Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.

Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immuno-oncology, auto-immunity, haematology, infectious disease and other areas.

For more information please see http://www.kymab.com

Find out which events we'll be attending this year

View events